Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥19,960, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 15x in the Chemicals industry in Japan. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥37,123 per share. お知らせ • Jun 27
C.Uyemura & Co.,Ltd. to Report Q1, 2027 Results on Aug 07, 2026 C.Uyemura & Co.,Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026 Buy Or Sell Opportunity • Jun 23
Now 23% undervalued Over the last 90 days, the stock has risen 17% to JP¥26,870. The fair value is estimated to be JP¥34,958, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 18%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to JP¥26,190, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in Japan. Total returns to shareholders of 236% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥37,830 per share. Major Estimate Revision • Jun 09
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥93.8b to JP¥98.4b. EPS estimate increased from JP¥929 to JP¥1,041 per share. Net income forecast to grow 20% next year vs 5.2% growth forecast for Chemicals industry in Japan. Consensus price target of JP¥24,300 unchanged from last update. Share price was steady at JP¥22,700 over the past week. Major Estimate Revision • Jun 08
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥93.8b to JP¥98.4b. EPS estimate increased from JP¥929 to JP¥1,041 per share. Net income forecast to grow 20% next year vs 5.3% growth forecast for Chemicals industry in Japan. Consensus price target of JP¥24,300 unchanged from last update. Share price fell 6.4% to JP¥21,800 over the past week. Reported Earnings • May 15
Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2026 results: EPS: JP¥865 (down from JP¥873 in FY 2025). Revenue: JP¥91.8b (up 9.5% from FY 2025). Net income: JP¥13.9b (flat on FY 2025). Profit margin: 15% (down from 17% in FY 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 1.6%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • May 13
C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 26, 2026 C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 26, 2026. お知らせ • May 09
C.Uyemura & Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 C.Uyemura & Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026 New Risk • Mar 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥290 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.3%). Price Target Changed • Mar 14
Price target increased by 18% to JP¥19,400 Up from JP¥16,500, the current price target is an average from 2 analysts. New target price is 12% below last closing price of JP¥22,130. Stock is up 115% over the past year. The company is forecast to post earnings per share of JP¥908 for next year compared to JP¥873 last year. Reported Earnings • Feb 10
Third quarter 2026 earnings released: EPS: JP¥278 (vs JP¥260 in 3Q 2025) Third quarter 2026 results: EPS: JP¥278 (up from JP¥260 in 3Q 2025). Revenue: JP¥24.3b (up 7.5% from 3Q 2025). Net income: JP¥4.49b (up 7.1% from 3Q 2025). Profit margin: 19% (in line with 3Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Feb 09
C.Uyemura & Co.,Ltd. (TSE:4966) announces an Equity Buyback for 260,000 shares, representing 1.61% for ¥4,000 million. C.Uyemura & Co.,Ltd. (TSE:4966) announces a share repurchase program. Under the program, the company will repurchase up to 260,000 shares, representing 1.61% of its issued share capital (excluding treasury stock), for ¥4,000 million. The purpose of the program is to improve shareholder profits by implementing agile capital policies and improving capital efficiency in response to changes in the business environment. The program will run until September 30, 2026. As of January 31, 2026, the company had 16,137,861 shares in issue (excluding treasury stock) and 1,961,139 shares in treasury. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to JP¥17,290, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 14x in the Chemicals industry in Japan. Total returns to shareholders of 186% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥27,734 per share. お知らせ • Dec 27
C.Uyemura & Co.,Ltd. to Report Q3, 2026 Results on Feb 09, 2026 C.Uyemura & Co.,Ltd. announced that they will report Q3, 2026 results on Feb 09, 2026 Declared Dividend • Nov 12
Dividend of JP¥280 announced Shareholders will receive a dividend of JP¥280. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 2.0%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover. お知らせ • Sep 26
C.Uyemura & Co.,Ltd. to Report Q2, 2026 Results on Nov 10, 2025 C.Uyemura & Co.,Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025 Price Target Changed • Aug 31
Price target increased by 8.6% to JP¥15,750 Up from JP¥14,500, the current price target is an average from 2 analysts. New target price is 50% above last closing price of JP¥10,490. Stock is down 1.9% over the past year. The company is forecast to post earnings per share of JP¥820 for next year compared to JP¥873 last year. Reported Earnings • Aug 10
First quarter 2026 earnings released: EPS: JP¥218 (vs JP¥233 in 1Q 2025) First quarter 2026 results: EPS: JP¥218 (down from JP¥233 in 1Q 2025). Revenue: JP¥20.1b (flat on 1Q 2025). Net income: JP¥3.52b (down 6.1% from 1Q 2025). Profit margin: 18% (down from 19% in 1Q 2025). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year and the company’s share price has also increased by 14% per year. お知らせ • Jul 02
C.Uyemura & Co.,Ltd. to Report Q1, 2026 Results on Aug 08, 2025 C.Uyemura & Co.,Ltd. announced that they will report Q1, 2026 results on Aug 08, 2025 Major Estimate Revision • Jun 12
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from JP¥86.7b to JP¥84.5b. EPS estimate also fell from JP¥890 per share to JP¥777 per share. Net income forecast to shrink 11% next year vs 6.1% growth forecast for Chemicals industry in Japan . Consensus price target of JP¥14,500 unchanged from last update. Share price was steady at JP¥8,800 over the past week. New Risk • May 25
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • May 13
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: JP¥873 (up from JP¥673 in FY 2024). Revenue: JP¥83.8b (up 4.5% from FY 2024). Net income: JP¥14.1b (up 29% from FY 2024). Profit margin: 17% (up from 14% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 13% per year. お知らせ • May 12
C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 27, 2025 C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 27, 2025. お知らせ • Apr 18
C.Uyemura & Co.,Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 C.Uyemura & Co.,Ltd. announced that they will report fiscal year 2025 results on May 12, 2025 Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥8,340, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Chemicals industry in Japan. Total returns to shareholders of 48% over the past three years. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥280 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Japanese dividend payers (3.7%). In line with average of industry peers (2.6%). Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: JP¥260 (vs JP¥198 in 3Q 2024) Third quarter 2025 results: EPS: JP¥260 (up from JP¥198 in 3Q 2024). Revenue: JP¥22.6b (up 9.2% from 3Q 2024). Net income: JP¥4.20b (up 31% from 3Q 2024). Profit margin: 19% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jan 17
Price target increased by 12% to JP¥14,450 Up from JP¥12,850, the current price target is an average from 2 analysts. New target price is 33% above last closing price of JP¥10,870. Stock is up 1.7% over the past year. The company is forecast to post earnings per share of JP¥834 for next year compared to JP¥673 last year. Major Estimate Revision • Dec 04
Consensus EPS estimates increase by 14% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from JP¥736 to JP¥837. Revenue forecast steady at JP¥83.0b. Net income forecast to shrink 4.5% next year vs 13% growth forecast for Chemicals industry in Japan . Consensus price target of JP¥11,850 unchanged from last update. Share price rose 2.1% to JP¥11,060 over the past week. お知らせ • Nov 28
C.Uyemura & Co.,Ltd. to Report Q3, 2025 Results on Feb 10, 2025 C.Uyemura & Co.,Ltd. announced that they will report Q3, 2025 results on Feb 10, 2025 Buy Or Sell Opportunity • Nov 21
Now 20% undervalued Over the last 90 days, the stock has risen 5.5% to JP¥11,140. The fair value is estimated to be JP¥13,973, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings are also forecast to grow by 4.0% per annum over the same time period. Declared Dividend • Nov 13
Dividend of JP¥200 announced Shareholders will receive a dividend of JP¥200. Ex-date: 28th March 2025 Payment date: 30th June 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 6.2% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to JP¥12,170, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Chemicals industry in Japan. Total returns to shareholders of 148% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥13,942 per share. Buy Or Sell Opportunity • Oct 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.9% to JP¥10,980. The fair value is estimated to be JP¥13,981, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings are also forecast to grow by 8.2% per annum over the same time period. Buy Or Sell Opportunity • Sep 24
Now 21% undervalued Over the last 90 days, the stock has risen 2.2% to JP¥11,140. The fair value is estimated to be JP¥14,025, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings are also forecast to grow by 8.2% per annum over the same time period. お知らせ • Aug 28
C.Uyemura & Co.,Ltd. to Report Q2, 2025 Results on Nov 11, 2024 C.Uyemura & Co.,Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024 Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to JP¥8,060, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Chemicals industry in Japan. Total returns to shareholders of 86% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥9,809 per share. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Jul 29
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 3.3% to JP¥10,730. The fair value is estimated to be JP¥8,654, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 2.6% per annum over the same time period. Buy Or Sell Opportunity • Jul 01
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 2.8% to JP¥10,790. The fair value is estimated to be JP¥8,600, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 2.6% per annum over the same time period. Buy Or Sell Opportunity • Jun 20
Now 24% overvalued Over the last 90 days, the stock has fallen 1.5% to JP¥10,650. The fair value is estimated to be JP¥8,563, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 2.6% per annum over the same time period. お知らせ • Jun 08
C.Uyemura & Co.,Ltd. to Report Q1, 2025 Results on Aug 08, 2024 C.Uyemura & Co.,Ltd. announced that they will report Q1, 2025 results on Aug 08, 2024 Buy Or Sell Opportunity • May 30
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to JP¥10,250. The fair value is estimated to be JP¥8,534, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. Revenue is forecast to grow by 9.2% in 2 years. Earnings are forecast to grow by 12% in the next 2 years. Reported Earnings • May 12
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: JP¥673 (up from JP¥637 in FY 2023). Revenue: JP¥80.3b (down 6.4% from FY 2023). Net income: JP¥10.9b (up 3.6% from FY 2023). Profit margin: 14% (up from 12% in FY 2023). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • May 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.1% to JP¥9,810. The fair value is estimated to be JP¥12,378, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 9.5%. Revenue is forecast to grow by 9.2% in 2 years. Earnings are forecast to grow by 12% in the next 2 years. お知らせ • May 12
C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 27, 2024 C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 27, 2024. Buy Or Sell Opportunity • Apr 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.9% to JP¥9,730. The fair value is estimated to be JP¥12,326, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 9.9% in 2 years. Earnings are forecast to grow by 35% in the next 2 years. お知らせ • Mar 28
C.Uyemura & Co.,Ltd. to Report Fiscal Year 2024 Results on May 10, 2024 C.Uyemura & Co.,Ltd. announced that they will report fiscal year 2024 results on May 10, 2024 Upcoming Dividend • Mar 21
Upcoming dividend of JP¥180 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.1%). Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: JP¥198 (vs JP¥177 in 3Q 2023) Third quarter 2024 results: EPS: JP¥198 (up from JP¥177 in 3Q 2023). Revenue: JP¥20.7b (down 9.5% from 3Q 2023). Net income: JP¥3.20b (up 9.6% from 3Q 2023). Profit margin: 16% (up from 13% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Dec 28
C.Uyemura & Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024 C.Uyemura & Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024 Major Estimate Revision • Dec 02
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥76.8b to JP¥78.4b. EPS estimate increased from JP¥476 to JP¥529 per share. Net income forecast to grow 8.3% next year vs 13% growth forecast for Chemicals industry in Japan. Consensus price target of JP¥10,000 unchanged from last update. Share price rose 4.4% to JP¥10,650 over the past week. Buying Opportunity • Nov 17
Now 21% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be JP¥12,214, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 4.8% in 2 years. Earnings is forecast to grow by 18% in the next 2 years. Reported Earnings • Nov 15
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: JP¥133 (down from JP¥140 in 2Q 2023). Revenue: JP¥19.7b (down 10% from 2Q 2023). Net income: JP¥2.16b (down 6.6% from 2Q 2023). Profit margin: 11% (in line with 2Q 2023). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Sep 23
C.Uyemura & Co.,Ltd. to Report Q2, 2024 Results on Nov 13, 2023 C.Uyemura & Co.,Ltd. announced that they will report Q2, 2024 results on Nov 13, 2023 Buying Opportunity • Sep 11
Now 20% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be JP¥12,189, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 0.4% in 2 years. Earnings is forecast to grow by 11% in the next 2 years. Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥115 (vs JP¥218 in 1Q 2023) First quarter 2024 results: EPS: JP¥115 (down from JP¥218 in 1Q 2023). Revenue: JP¥17.5b (down 13% from 1Q 2023). Net income: JP¥1.90b (down 48% from 1Q 2023). Profit margin: 11% (down from 18% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Jun 28
C.Uyemura & Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023 C.Uyemura & Co.,Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023 New Risk • Jun 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • May 16
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: JP¥637 (up from JP¥560 in FY 2022). Revenue: JP¥85.7b (up 19% from FY 2022). Net income: JP¥10.5b (up 8.9% from FY 2022). Profit margin: 12% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 7.5%. Revenue is forecast to stay flat during the next 2 years compared to a 3.7% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year and the company’s share price has also increased by 28% per year. お知らせ • May 14
C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 29, 2023 C.Uyemura & Co.,Ltd., Annual General Meeting, Jun 29, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥180 per share at 1.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 9.7% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.8%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥177 (vs JP¥160 in 3Q 2022) Third quarter 2023 results: EPS: JP¥177 (up from JP¥160 in 3Q 2022). Revenue: JP¥22.8b (up 23% from 3Q 2022). Net income: JP¥2.92b (up 5.7% from 3Q 2022). Profit margin: 13% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. お知らせ • Dec 04
C.Uyemura & Co.,Ltd. to Report Q3, 2023 Results on Feb 10, 2023 C.Uyemura & Co.,Ltd. announced that they will report Q3, 2023 results on Feb 10, 2023 Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. No independent directors (9 non-independent directors). External Director Akihiko Takahashi was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2023 results: EPS: JP¥140 (down from JP¥141 in 2Q 2022). Revenue: JP¥21.9b (up 27% from 2Q 2022). Net income: JP¥2.32b (down 4.5% from 2Q 2022). Profit margin: 11% (down from 14% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. お知らせ • Sep 28
C.Uyemura & Co.,Ltd. to Report Q2, 2023 Results on Nov 11, 2022 C.Uyemura & Co.,Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Aug 09
First quarter 2023 earnings released: EPS: JP¥218 (vs JP¥121 in 1Q 2022) First quarter 2023 results: EPS: JP¥218 (up from JP¥121 in 1Q 2022). Revenue: JP¥20.2b (up 28% from 1Q 2022). Net income: JP¥3.66b (up 73% from 1Q 2022). Profit margin: 18% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 5.6%, compared to a 9.3% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 32% per year. お知らせ • Jun 30
C.Uyemura & Co.,Ltd. to Report Q1, 2023 Results on Aug 08, 2022 C.Uyemura & Co.,Ltd. announced that they will report Q1, 2023 results on Aug 08, 2022 Major Estimate Revision • Jun 04
Consensus EPS estimates increase by 25% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from JP¥75.2b to JP¥78.5b. EPS estimate increased from JP¥604 to JP¥754 per share. Net income forecast to grow 34% next year vs 5.9% growth forecast for Chemicals industry in Japan. Consensus price target of JP¥7,224 unchanged from last update. Share price rose 4.4% to JP¥7,340 over the past week.